Because RT can induce immunogenic cell death in cancer cells, and it is well established that immune cells are crucial for the antitumor effect of RT (Demaria et al., 2015), we decided to investigate both GVAX and RT as T cell–priming agents in combination regimens that included αPD-1 and CCR2/5i in mouse models of PDAC. This evidence concerns the gene CCR2 and cancer.